

Curriculum Vitae

Personal
information

Matitiahu Berkovitch

Work
experience

1983-1988	Specialization in Pediatrics, Pediatric Division, Assaf Harofeh Medical Center
1.4.88-30.6.92	Senior Medical Officer in the Pediatric Day-Care Unit at Assaf Harofeh Medical Center
1.7.92-30.6.94	Fellowship in Clinical Pharmacology and Toxicology, The Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Canada
1.7.94-10.10.99	Senior Medical Officer in the Pediatric Day care department, Assaf Harofeh Medical Center.
1995	Lecturer Sackler school of Medicine, Tel-Aviv University.
1999	Specialist in Clinical Pharmacology
1999- 2003	Senior Lecturer, School of Medicine, Tel-Aviv University
1999- present	Director – Clinical Pharmacology and Toxicology Unit, Assaf Harofeh Medical Center
1999-present	Member- Drug and Therapeutic Committee, Assaf Harofeh Medical Center
2003- 2006	Chairman- Pediatric Division, Assaf Harofeh Medical Center.
2003- 2011	Associate Clinical Professor in Sackler school of Medicine, Tel-Aviv University
2011- 2018	Associate Professor, School of Medicine, Tel-Aviv University.
2019- present	Full Professor, School of Medicine, Tel-Aviv University
2006- 2010	Member of the Committee of ESDP- European Society of Developmental Pharmacology
2008- 2014	Chairman, Teachers-Students Committee, Sackler School of Medicine, Tel-Aviv University.
2008-2014	Vice Dean for Academic Education at Assaf Harofeh Medical Center, Sackler School of Medicine, Tel-Aviv University.
2014-present	Chairman, National Advisory Committee of Drug Registration, Ministry of Health
2014-present	Chairman, National Advisory Committee on Adverse Drug Reactions, Ministry of Health

Education
and
training

Periods of Studies

(Name of University, City, Country)

Period

Subject - Medicine

University of Rome, Rome, Italy

1975 - 1978

Tel-Aviv University, Israel

1978 - 1982

Degree or Professional License MD

Date Awarded 5.7.1983

Additional information

Publications

B.1. Articles Published:

1. Berkovitch M, Rubinstein EE, Lahat E, Aladjem M.
Plasma concentration of orally administered Gentamycin in infants with diarrhea. IMAJ. 1993; 218.
2. Berkovitch M, Matsui D, Lamm SH, Rosa F, Koren G.
Recent increase in numbers and risk of fatalities in young children ingesting iron preparations. Toxicol. 1993; 36: 53-55.
3. Berkovitch M, Laxer R, Inman R, Koren G, Pritzker KPH, Fritzler MJ, Olivieri NF. Arthropathy in thalassemia patients receiving deferiprone. Lancet. 1994; 343:1471-1472.
4. Berkovitch M, Pastuszak A, Gazarian M, Lewis M, Koren G.
Safety of the new quinolones in pregnancy. Obstet Gynecol. 1994; 84: 535-538.
5. Matsui D, Hermann C, Klein J, Berkovitch M, Olivieri N, Koren G.
Critical comparison of novel and exciting method of compliance measurement during a clinic an oral iron chelator. J Clin Pharmacol. 1994; 34:944-946.
6. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McClellan Liu PP, Tempelton DM, Koren G.
Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med. 1995; 332: 918-922.
7. Berkovitch M, Matsui D, Fogelman R, Komar L, Hamilton R, Johnson D.
Assessment of the terminal 40-millisecond QRS vector in children with a history of tricyclic antidepressant ingestion. Pediatr Emerg Care. 1995; 11:75-77.
8. Lahat E, Avital E, Barr J, Berkovitch M, Arlazarof A, Aladjem M.
BAEP studies in children with attention deficit disorder. Dev Med Child Neurol. 1995; 37:119-123.
9. Gazarian M, Berkovitch M, Koren G, Silverman ED, Laxer RM.
Experience with misoprostol therapy for NSAID gastropathy in children. Ann Rheum Dis. 1995; 54: 277-280.
10. Berkovitch M, Davis S, Matsui D, Donsky J, Koren G, Olivieri NF.

- Use of EMLA for chronic subcutaneous drug administration.
J Clin Pharmacol. 1995; 35: 295-297.
11. Press J, Berkovitch M, Laxer R, Giesbrecht E, Silverman E, Klein J, Koren G. Evaluation of therapeutic drug monitoring of methotrexate in saliva of children with rheumatic diseases. Ther Drug Monit. 1995; 17: 247-250.
 12. Berkovitch M, Pope E, Phillips J, Koren G.
Pemoline-associated fulminant liver failure: Testing the evidence for causation.
Clin Pharmacol Ther. 1995. 57:696-698.
 13. Berkovitch M, Keresteci AG, Koren G. Efficacy of prilocaine-lidocaine cream in the treatment of premature ejaculation. J Urol. 1995; 154:1360-1361.
 14. Bistrizer T, Berkovitch M, Barr J, Lahat E.
Focal epileptic episodes associated with hypoglycemia in children with diabetes. Clin Neurol Neurosurg. 1995. 97:314-316.
 15. Fassos FF, Berkovitch M, Daneman N, Koren L, Cameron RG, Falcitelli C, St.Louis P, Daneman N, Koren G.
Efficacy of deferiprone in the treatment of acute iron intoxication in rats.
J Toxicol Clin Toxicol. 1996; E34: 279-287.
 16. Berkovitch M, Matsui D, Zipursky A, Blanchette VS, Verjee Z, Giesbrecht E, Saunders EF, Eshel G, Koren G. Hepatotoxicity of 6- Mercaptopurine in childhood acute lymphocytic leukemia: Pharmacokinetic characteristics.
Med Pediatr Oncol. 1996; 26: 85-89.
 17. Berkovitch M, Sher GD, McClelland R, Matsui D, Hadzialic G, Olivieri NF, Koren G.
Pharmacokinetics of arginine butyrate in patients with hemoglobinopathy. Environ Toxicol Pharmacol. 1996; 2:403-405.
 18. Pope E, Berkovitch M, Klein J, Fassos FF, Koren G.
Salivary measurement of deferiprone concentrations and its correlation with serum levels. Ther Drug Monitor. 1997; Kozer E,19:95-97.
 19. Berkovitch M, Livne A, Lushkov G, Barr J, Tauber T, Eshel G, Koren G, Bistrizer T. Acute iron intoxication: significant differences between sexes.
Vet Hum Toxicol. 1997; 39: 265-267.
 20. Sela BA, Lerman-Sagie T, Berkovitch M. Carnitin deficiency in inborn errors of metabolism. J Inher Metab Dis. 1997; 133: 419-423.
 21. Barr J, Lushkov G, Starinsky R, Klin B, Berkovitch M, Eshel G.
Heliox therapy for pneumothorax - a new indication for an old remedy: an animal study. Ann N Y Acad Med. 1997; 30:159-162.
 22. Loebenstein R, Dalal I, Nisbet-Brown E, Berkovitch M, Meidan N, Andrews D, Koren G, Roitman J, Olivieri NF. Immune function in patients with β -thalassemia receiving the orally active iron-chelating agent deferiprone.
Br J Haematol. 1997; 98:597-600.
 23. Berkovitch M, Papadouris JD, Shaw D, Onuaha N, Dias C, Olivieri NF.

- Improving compliance with prophylactic oral penicillin in children with sickle-cell disease: A
Br J Clin Pharmacol. 1998; 45:605-607.
24. Berkovitch M, Bistritzer T, Aladjem M, Burtin P, Dagan T, Chen-Levi Z, Freedom R,
Clinical relevance of therapeutic drug monitoring of digoxin and gentamicin in saliva of
Ther Drug Monit. 1998; 20:253-256 .
 25. Fassos FF, Berkovitch M, Daneman N, Koren L, Cameron R, Klein J, Falcitelli C, St. Louis
Koren. The efficacy of diazepam in the treatment of acute iron overload in rats. Can J Physiol
1998; 76:895-899.
 26. Adamkiewicz T, Berkovitch M, Krishnan C, Polsinelli C, Kermack D, Olivieri NF. Infection
Yersinia enterocolitica in a series of patients with betathalassemia: incidence and predisposing
Clin Infect Dis. 1998; 27:1362-1366.
 27. Lahat E, Goldman M, Barr J, Eshel G, Berkovitch M.
Intranasal midazolam for childhood seizures. Lancet. 1998; 352: 620, Kozer E,
 28. Nulman I, Berkovitch M, Klein J, Pastuszak A, Lester RS, Shear N,
Koren G. Steady-state pharmacokinetics of isotretinoin and its 4-oxo metabolite: implications
safety. J Clin Pharmacol. 1998; 38:926-930.
 29. Berkovitch M, Copeliovitch L, Tauber T, Vaknin Z, Lahat E. Hereditary insensitivity to pain
anhidrosis. Pediatr Neurol. 1998; 19:227-229.
 30. Berkovitch M, Vaida A, Svotzic D, Dagan T, Bar-Yochai A, Boldur I.
Group A Streptococcal pharyngotonsillitis in infants more common than is thought. Clin Ped
38:361-363.
 31. Kozer E, Lahat E, Berkovitch M. Hypertension and abdominal pain:
uncommon presentation after exposure to a pine caterpillar._
Toxicol. 1999; 37:1797-1801.
 32. Lahat E, Barr J, Berzilai A, Cohen H, Berkovitch M.
Visual-Evoked Potentials in the Diagnosis of Headaches before 5 years of age. Eur J Pediatr.
1999; 158: 892-895.
 33. Barr J, Berkovitch M, Tavori I, Kariv N, Schejter A, Eshel G.
Acute iron intoxication: the efficacy of deferiprone and sodium bicarbonate in the prevention
absorption from the digestive tract. Vet Human Toxicol. 1999; 41:308-311.
 34. Berkovitch M, Dolinski G, Tauber T, Aladjem M, Kaplinsky H.
Neutropenia as a complication of intravenous immunoglobulin (IVIG) therapy in children with
immune thrombocytopenic purpura: common and non-alarming. Int J Immunopharmacol. 1999
21:411-415.
 35. Ringel S, Lahat E, Elizov T, Greenberg R, Arieli S, Afriat R, Berkovitch M. Awareness of fo
neural tube defect prevention among Israeli women. Teratology. 1999; 60:29-32.
 36. Berkovitch M, Reznik S, Lushkov G, Koren G.
The effect of diazepam in the recovery of rabbits from acute acetaminophen intoxication. The
Monit. 1999; 21:267-273.
 37. Bistritzer T, Berkovitch M, Rappoport MJ, Evans S, Arieli S, Goldberg M,

- Tavori I, Aladjem M. Sodium potassium adenosine triphosphatase activity in preterm and term newborns and its possible role in sodium homeostasis during maturation. *Arch Dis Child Fetal Neonatal*. 1998; 81:184-187.
38. Lahat E, Berkovitch M, Barr J, Paret G, Barzilai A.
Abnormal visual evoked potentials in children with "Alice in Wonderland" syndrome due to iron overload and mononucleosis. *J Child Neurol*. 1999; 14:732-735,
 39. Lahat E, Goldman M, Barr J, Bistritzer T, Berkovitch M. Intranasal midazolam as a treatment for autonomic crises in patients with familial dysautonomia. *Pediatr Neurol*. 2000; 22:19-22.
 40. Berkovitch M, Bistritzer T, Milone SD, Perlman K, Kucharczyk W, Liu PP, Collins AF, Kornblum R, Olivieri NF. Iron deposition in the anterior pituitary in homozygous beta thalassemia: MRI evaluation and correlation with gonadal function. *J Pediatr Endocrinol Metab*. 2000; 13:179-184
 41. Berkovitch M, Livne A, Lushkov G, Koren G. The efficacy of oral deferiprone acute iron toxicity in rats. *Am J Emerg Med*. 2000; 18:36-40.
 42. Barr J, Berkovitch M, Matras H, Kocer E, Greenberg R, Eshel G.
Talismans and amulets in the pediatric intensive care unit: legendary powers in contemporary medicine. *IMAJ*. 2000; 2:287-281.
 43. Eshel G, Barr J, Chazan S, Tavori I, Kariv N, Schechter A, Greenberg R, Berkovitch M. Efficacy of orally administered deferoxamine, activated charcoal and sodium bicarbonate in acute iron poisoning in rats: implications for the pediatric iron poisoning. *Curr Ther Res*. 2000; 61:648-656.
 44. Berkovitch M, Goldman M, Silverman R, Chen-Levi Z, Greenberg R, Markus O, Lahat E. Therapeutic drug monitoring of once daily gentamicin in serum and saliva of children. *Eur J Pediatr*. 2000; 167:691-698.
 45. Berkovitch M, Elbirt D, Addis A, Schuler-Faccini L, Or-Noy A.
Fetal effects of metoclopramide therapy for nausea and vomiting of pregnancy. *N Engl J Med*. 2000; 343:445-446.
 46. Berkovitch M, Segal-Socher I, Greenberg R, Bulkowshtein M, Arnon J, Merlob P, Or-Noy A.
First trimester exposure to cefuroxime: a prospective cohort study. *Br J Clin Pharmacol*. 2000; 50:161-165.
 47. Berkovitch M, Uziel Y, Tavori I, Chen-Levy Z, Greenberg R, Marcus O, Pinto Evans S, Lahat E. High blood salicylate levels in neonates with hyperbilirubinemia. *Ther Drug Monit*. 2000; 22:100-104.
 48. Lahat E, Goldman M, Barr J, Bistritzer T, Berkovitch M.
Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: a prospective randomized study. *BMJ*. 2000; 321:83-86.
 49. Tauber T, Lahat E, Dolinsky G, Karpuch J, Frenkel Y, Berkovitch M.
Haemophilus influenza type b vaccine in Israel: experience in a paediatric ambulatory clinic. *Tropical Paediatr*. 2001; 21:231-234.
 50. Ringel S, Kahan E, Greenberg R, Blay A, Berkovitch M.
Breast feeding and smoking habits among Israeli women. *IMAJ*. 2001; 3:739-742.

51. Berkovitch M, Press J, Bulkowshtein M, Even L, Barash J, Brik J, Tasher D, Marom R, AS, Hecht Y, Rubinstein M, Mosleh M, Ben-Shachar S, Talmor R, Zviel A, Kiro A, Piglanski P, Pinski V, Uziel J. Premarketing surveillance of oral ibuprofen solution in febrile children. *Clin Invest*. 2001; 21:821-825.
52. Berkovitch M, Greenberg R, Gendle L, Avgil M, Bulkowstein M, Sthal B, Kessler A, Merlob P. Sore throat treatment during pregnancy: a prospective, controlled, pilot study. *Clin Drug Invest*. 2002; 22:135-139.
53. Barr J, Brenner-Zada G, Heiman E, Pareth G, Bulkowstein M, Greenberg R, Berkovitch M. Unliscence and off-label medications in neonatal intensive care unit. *Am J Perinat*. 2002; 19:672.
54. Eshel G, Reisler G, Berkovitch M, Shapira S, Grauer E, Barr J. Comparison of fast versus slow rewarming following acute moderate hypothermia in rats. *Pa Anaesth*. 2002; 12:235-242.
51. Eshel G, Raviv R, Ben-Abraham R, Barr J, Berkovitch M, Efrati O, Vardi A, Barzilay Z, Paret G. Inadequate asthma treatment practices and compliance in Israel. *Pediatr Pulmonol*. 2002; 33:85-89.
52. Berkovitch M, Bulkowstein M, Zovtitz D, Greenberg R, Nitzan Y, Barzilay B, Boldor I. Colonization rate of bacteria in the throat of healthy infants. *Int J Pediatr Otorhinolaryngol*. 2002; 63:19-24.
53. Kozer E, Barr J, Bulkowstein M, Avgil M, Greenberg R, Matias, Petrov I, Berkovitch M. A prospective study of multiple supratherapeutic acetaminophen doses in febrile children. *Vet Hum Toxicol*. 2002; 44:106-109.
54. Berkovitch M, Mazzota P, Greenberg R, Elbirt D, Addis A, Schuler-Faccini L, Merlob P, Arnon J, Stahl B, Magee L, Moretti M, A. Ornoy A. Metoclopramide for nausea and vomiting in pregnancy: a prospective multicenter international study. *Am J Perinatol*. 2002; 19:311-316.
55. Bistrizer T, Kerem E, Berkovitch M, Rapoport MJ, Evans S, Aladjem M. Erythrocyte Na⁺, K⁺-ATPase and nasal potential in pseudohypoaldosteronism. *Clin Endocrinol (Oxf)*. 2002; 56:575-580.
56. Berkovitch M, Dafni O, Leiboviz A, Mayan H, Habut B, Segal R. Therapeutic drug monitoring of theophylline in frail elderly patients: oral as compared to nasogastric tube administration. *Ther Drug Monit*. 2002; 24:594-597.
57. Manisterski Y, Vaknin Z, Ben-Abraham R, Efrati O, Lotan D, Berkovitch M, Barak A, Barzilay Z, Paret G. Endotracheal epinephrine: a call for larger doses. *Anesth Analg*. 2002; 95:1037-1041.
58. Efrati O, Barak A, Ben-Abraham R, Modan-Moses D, Berkovitch M, Manisterski Y, Lotan D, Barzilay Z, Paret G. Should vasopressin replace adrenaline for endotracheal drug administration? *Crit Care Med*. 2003; 31:572-573.
59. Uziel Y, Berkovitch M, Gazarian M, Koren G, Silverman ED, Schneider R, Laxer RM. Evaluation of eutectic lidocaine/prilocaine cream (EMLA) for steroid joint injection in children with juvenile rheumatoid arthritis: a double blind, randomized, placebo, controlled trial. *J*

- Rheumatol. 2003; 30:594-596.
60. Gidron Y, Berkovitch M, Press L. Psychosocial correlates of incidence of attacks in children with Familial Mediterranean Fever. J Behav Med. 2003; 26:95-104.
 61. Berkovitch M, Heyman E, Afriat R, Matz-Khromchenko I, Avgil M, Greenberg R, Zimmerman DR, Berman S, Weissgarten J. Zinc and copper plasma levels among children with nonorganic failure to thrive. Clin Nutr. 2003; 22:183-186.
 66. Kozar E, Evans S, Barr J, Greenberg R, Soriano I, Bulkowstein M, Petrov I, Chen-Levi Z, Barz Berkovitch M. Glutathione, glutathione-dependent enzymes and antioxidant status in erythrocytes of children treated with high-dose paracetamol. Br J Clin Pharmacol. 2003; 55:234-240.
(**PHARMACOLOGY & PHARMACY 66/237, IF 3.246**)
 67. Moretti ME, Caprara D, Coutinho CJ, Bar-Oz B, Berkovitch M, Addis A, Jovanovski E, Schulz F, Faccini L, Koren G. Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study. J Allergy Clin Immunol. 2003; 111:479-483. (**ALLERGY 1/21, IMMUNOLOGY 8/128, 9.165**).
 68. Hashkes PJ, Tauber T, Somekh E, Brik R, Barash J, Mukamel M, Harel L, Lorber A, Berkovitch M, Uziel Y. Naproxen as an alternative to aspirin for the treatment of arthritis of rheumatic fever: a randomized trial. J Pediatr. 2003; 143:399-401. (**PEDIATRICS 4/94, IF 4.092**).
 69. Segal R, Lubart E, Leibovitz A, Berkovitch M, Habot B, Yaron M, Caspi D. Early and late effects of low-dose aspirin on renal function in elderly patients. Am J Med. 2003; 115: 462-466.
(**MEDICINE , GENERAL & INTERNAL 14/133, IF 4.466**)
 70. Heyman E, Morag I, Batash D, Keidar R, Baram S, Berkovitch M. Closure of patent ductus arteriosus with oral ibuprofen suspension in premature newborns: a pilot study. Pediatrics. 2003; 111:e354. (**PEDIATRICS 3/94, IF 4.687**)
 71. Gavrilov V, Berkovitch M, Ling G, Zadda G, Lifshitz M, Gorodischer R. Unapproved prescriptions in two pediatric intensive care units in Israel. Curr Ther Res. 2003; 64:734-742. (**PHARMACOLOGY & PHARMACY 231/237, MEDICAL RESEARCH & EXPERIMENTAL 90/93, IF 0.238**)
 72. Berkovitch M, Diav-Citrin O, Greenberg R, Cohen M, Bulkowstein M, Shechtman S, Bortnik O, Arnon J, Ornoy A. First trimester exposure to amoxicillin/clavulanic acid: a prospective controlled study. **Brit J Clin Pharmacol** 2004;58(3):298- 302.(**IF- 3.246, PHARMACOLOGY&PHARMACY 66/236**).
 73. Kozar E, Mordel A, Haim SB, Bulkowstein M, Berkovitch M, Bentur Y. Pediatric poisoning from trimedoxime (TMB4) and atropine automatic injectors. J Pediatr. 2005; 146: 41-44. (**PEDIATRICS 4/94, IF 4.092**)
 74. Bar-Oz B, Clementi M, Di Gianantonio E, Greenberg R, Beer M, Merlob P, Arnon J, Ornoy A, Zuckerman DM, Berkovitch M. Metamizol (dipyrone, opalgin) in pregnancy, is it safe? A prospective comparative study. Eur J Gynecol Reprod Biol. 2005; 119:176-179. (**OBSTETRICS & GYNECOLOGY 39/70, IF 1.5**)

75. Benyamini L, Merlob P, Stahl B, Braunstein R, Bortnik O, Bulkowstein M, Zimmerman D, Berkovitch M. The safety of amoxicillin/clavulanic acid and cefuroxime during lactation. *Ther Drug Monit*. 2005; 27:499-502.
(**MEDICAL LABORATORY TECHNOLOGY 6/29, IF 2.429**)
76. Ben-Abraham R, Stepensky D, Assoulin-Dayana Y, Efrati O, Lotan D, Manisterski Y, Berkovitch M, Barzilay Z, Paret G. Beta1- or beta2-blockers to improve hemodynamics following endotracheal adrenaline administration. *Drug Metabol Drug Interact*. 2005; 21:31-39.
77. Greenberg R, Grossman Z, Goldstein L, Berkovitch M, Kozar E. How much acetaminophen do paediatricians prescribe? A survey among Israeli paediatricians. *Pharm Ther*. 2005; 30:443-446.
(**PHARMACOLOGY & PHARMACY 157/237, IF 1.671**)
78. Bentur Y, Layish I, Krivoy A, Berkovitch M, Rotman E, Haim SB, Yehezkelli Y, Kozar E. Ciprofloxacin self injections of atropine-trimethoprim (TMB4) auto-injectors. *Clin Toxicol*. 2006; 44:301-311.
(**TOXICOLOGY 56/77, IF 1.460**)
79. Vaknin Z, Halperin R, Schneider D, Teitler J, Dar P, Herman A, Berkovitch M. Hyperemesis gravidarum and nonspecific abnormal EEG findings: a preliminary report. *J Reprod Med*. 2006; 51:623-630.
(**OBSTETRICS & GYNECOLOGY 58/70, IF 0.696**)
80. Goldstein LH, Elias M, Ron-Avraham G, Biniaurishvili BZ, Madjar M, Kamargash I, Braunstein R, Berkovitch M, Golik A. Consumption of herbal remedies and dietary supplements amongst patients hospitalized in medical wards. *Br J Clin Pharmacol*. 2007; 64:371-376.
(**PHARMACOLOGY & PHARMACY 66/236 IF 3.246**)
81. Kozar E, Hahn Y, Berkovitch M, Chaim AB, Brandriss N, Verjee Z, Mor A, Goldman M. The relationship between acetaminophen concentrations in the cerebrospinal fluid and temperature decline in febrile infants. *Ther Drug Monit*. 2007; 29:819-823. (**MEDICAL LABORATORY TECHNOLOGY 6/29, IF 2.429**)
82. Goldstein LH, Dolinsky G, Greenberg R, Schaefer C, Cohen-Kerem R, Diav-Citrin O, Malm H, Lodewijks ME, Rost van Tonningen-van Driel MM, Amnon J, Ornoy A, Clementi M, Di Gianfrancesco A, Koren G, Braunstein R, Berkovitch M. Pregnancy outcome of women exposed to azathioprine during pregnancy. *Birth Defects Res. Part A – Clin Mol Teratol*. 2007;79:696-701. (**TOXICOLOGY 56/77, IF 1.460**)
83. Garcia-Bournissen F, Tsur L, Goldstein LH, Staroselsky A, Avner M, Asrar F, Berkovitch M, Straface G, Koren G, De Santis M. Fetal exposure to isotretinoin – an international problem. *Reprod Toxicol*. 2008; 25:124-128.
(**REPRODUCTIVE BIOLOGY 4/26, TOXICOLOGY 15/77, IF 3.367**)
84. Tsur L, Kozar E, Berkovitch M. The effect of drug consultation center guidance on contraceptive use among women using isotretinoin: a randomized, controlled study. *J Wom Health*. 2008; 17:571-576.
(**OBSTETRICS & GYNECOLOGY 32/70, IF 1.770**)
85. Bar-Oz B, Diav-Citrin O, Shechtman S, Tellem R, Arnon J, Francetic I, Berkovitch M, Ornoy A. Pregnancy outcome after gestational exposure to the new macrolides: a prospective multi-centre observational study. *Eur J Obstet Gynecol Reprod Biol*. 2008; 141:31-34. (**OBSTETRICS & GYNECOLOGY 32/70, IF 1.770**)

GYNECOLOGY 39/70, IF 1.582)

86. Goldstein LH, Berlin M, Berkovitch M, Kozer E. Effectiveness of oral vs rectal acetaminophen analysis.
Arch Pediatr Adolesc Med. 2008; 162:1042-1046. **(PEDIATRICS 2/94, IF 4.726)**
87. Weinbaum S, Kozer E, Evans S, Bar-Haim A, Zandback Y, Lahat E, Petrov I, Alkan Y, Siman Rechavi M, Goldstein L, Berkovitch M. Depletion of glutathione system enzymes of the liver and erythrocytes in a rat model of acute iron poisoning. Toxicol Mech Methods. 2008;18:623-626.
(TOXICOLOGY 71/77, IF 0.752)
88. Youngster I, Berkovitch M, Heyman E, Lazarovitch Z, Goldman M. The stethoscope as a vector of infectious diseases in the paediatric division.
Acta Paediatr. 2008; 9:1253-1255. **(PEDIATRICS 34/94, IF 1.768)**
89. Bar-Oz B, Goldman M, Lahat E, Greenberg R, Avgil M, Blay A, Herman A, Berkovitch M. Memory errors and response bias: the tip of the iceberg. _
IMAJ. 2008; 10:771-774. **(MEDICINE, GENERAL & INTERNAL 81/133, IF 0.898)**
90. Kozer E, Bar-Hamburger R, Rosenfeld NY, Zdanovitch I, Bulkowstein M, Berkovitch M. Illicit alcohol users admitted to the pediatric emergency department. IMAJ. 2008; 10:779-782.
(MEDICINE, GENERAL & INTERNAL 81/133, IF 0.898)
91. Toledano M, Kozer E, Goldstein LH, Abu-Kishk I, Bar-Haim A, Siman-Tov Y, Rechavi M, Re Weizer-Stern O, Berkovitch M.
Hepcidin in acute iron toxicity. Am J Emerg Med. 2009; 27:761-4.
(EMERGENCY MEDICINE 5/19, IF 1.542)
92. Goldstein LH, Berlin M, Tsur L, Bortnik O, Binyamini L, Berkovitch M.
The safety of macrolides during lactation. Breastfeed Med. 2009; 4:197-200.
93. Zimmerman DR, Goldstein L, Lahat E, Braunstein R, Stahi D, Bar-Haim A, Berkovitch M. Effect of 24+ hour fast on breast milk composition.
J Hum Lact. 2009; 25:194-198. **(NURSING 29/72, IF 1.014)**
94. Ben-Assa E, Youngster I, Kozer E, Abu-Kishk I, Bar-Haim A, Bar-Oz B, Berkovitch M. Change in serum hepcidin levels in acute iron intoxication in a rat model. Toxicol Lett. 2009; 189 :242-247.
(TOXICOLOGY 14/77, IF 3.479)
95. Kozer E, Bar-Hamburger R, Rosenfeld N, Dalal I, Landau O, Fainmessenger P, Ben-Yehuda Y, Berkovitch M. Strategy for increasing detection rates of drug and alcohol abuse in paediatric emergency department. Acta Paediatr. 2009; 98:1637-1640. **(PEDIATRICS 34/94, IF 1.768)**
96. Youngster I, Berkovitch M, Kozer E, Lazarovitch Z, Berkovitch S, Goldman M. Can religious beliefs be vectors of infectious diseases in hospital settings?
Am J Infect Control. 2009; 37:861-863. **(INFECTIOUS DISEASES 17/52, IF 3.013)**
97. Sarkar M, Koren G, Kalra S, Ying A, Smorlesi C, De Santis M, Diav-Citrin O, Avgil M, Voyer S, Berkovitch M, Einarson A. Montelukast use during pregnancy: a multicentre, prospective, cohort study of infant outcomes.
Eur J Clin Pharmacol. 2009; 65:1259-1264.
(PHARMACOLOGY & PHARMACY 58/237, IF 3.442)

98. Lubart E, Berkovitch M, Leibovitz A, Orly D, Segal R. Phenytoin blood concentration in hospital geriatric patients: oral versus nasogastric feeding tube administration. *Ther Drug Monit.* 2010; 32:185-188.
(MEDICAL LABORATORY TECHNOLOGY 6/29, IF 2.429)
99. Aviner S, Berkovitch M, Dalkian H, Braunstein R, Lomnicki Y, Schlesinger M. Use of a home preparation for "infantile colic" and an apparent life-threatening event. *Pediatrics.* 2010; 125: e11-e15.
(PEDIATRICS 3/94, IF 4.687)
100. Abu-Kishk I, Kozer E, Goldstein LH, Weinbaum S, Bar-Him A, Alkan Y, Petrov I, Evans S, Shapira Y, Berkovitch M. Oral N-acetylcysteine has a deleterious effect in acute iron intoxication in rats. *Emerg Med.* 2010; 28:8-12.
(EMERGENCY 5/19, IF 1.542)
101. Abu-Kishk I, Goldman M, Mordish Y, Berkovitch M, Kozer E. Transient renal insufficiency following dipyrone overdose. *Arch Dis Child.* 2010; 95:233-234. **(PEDIATRICS 12/94, IF 2.657)**
102. Cassina M, De Santis M, Cesari E, Van Eijkeren M, Berkovitch M, Eleftheriou G, Raffagnato I, Gianantonio E, Clementi M. First Trimester diclofenac exposure and pregnancy outcome. *Reprod Toxicol.* 2010; 30:401-404. **(REPRODUCTIVE BIOLOGY 4/26, IF 3.367)**
103. Ratz Y, Shafir I, Berkovitch S, Sharristh M, Kozer E, Golik A, Berkovitch M, Bar-Haim S. The Importance of the Pharmacist in Reporting Adverse Drug Reactions in the Emergency Department. *Pharmacol.* 2010; 50:1217-1221.
(PHARMACOLOGY & PHARMACY 58/237, IF 3.442).
104. Youngster I, Abu-Kishk I, Kozer E, Braunstein R, Bar-Haim A, Berkovitch M. Hyperbaric oxygen treatment reduced mortality in acute iron intoxication in rats. *Basic Clin Pharmacol Toxicol.* 2011; 107:737-741. **(TOXICOLOGY 36/77, PHARMACOLOGY & PHARMACY 121/237, IF 2.308)**
105. Diav-Citrin O, Shechtman S, Schwartz V, Avgil-Tsadok M, Finkel-Pekarsky V, Wajnberg R, Berkovitch M, Ornoy A. Pregnancy outcome after in utero exposure to colchicine. *Am J Obstet Gynecol.* 2010; 203:144. e1-6.
(OBSTETRICS & GYNECOLOGY 7/70, IF 3.278)
106. Maor Y, Raz M, Rubinstein E, Derazne E, Ringel S, Roizin H, Rahav G, Regev-Yochay G, Berkovitch M, Israeli Judicious Antibiotic Prescription study group. [Changing parents' opinions regarding antibiotic use in primary care.](#) *Eur J Pediatr.* 2011; 170:359-364. **(PEDIATRICS 38/94, IF 1.634)**
107. Hadas D, Youngster I, Cohen A, Leibovitch E, Shavit I, Uziel Y, Berkovitch M. Premarketing surveillance of ibuprofen suppositories in febrile children. *Clin Pediatr.* 2011; 50: 196-199. **(PEDIATRICS 66/94, IF 0.977)**
108. Breitbart R, Kozer E, Abu-Kishk I, Ben-Assa E, Goldstein LH, Youngster I, Berkovitch M. Intraperitoneal N-acetylcysteine for Acute Iron Intoxication in Rats. *Drug Chem Toxicol.* 2011; 34(4):429-32. **(CHEMISTRY, MULTIDISCIPLINARY 70/140, IF 1.250)**
109. Barzilay B, Youngster I, Batash D, Keidar R, Baram S, Berkovitch M, Heiman E. Pharmacokinetics of oral ibuprofen for the closure of patent ductus arteriosus in premature infants. *Pharmacol Ther.* 2011; 111:105-111.

Dis Child Fetal Neonatal Ed. (**PEDIATRICS 16/109, IF 2.616.**

110. Lifshitz AE, Goldstein LH, Sharist M, Strugo R, Asulin E, Haim SB, Feigenberg Z, Berkovitch M, Kozer E. Medication prescribing errors in the prehospital setting and in the ED. Am J Emerg **EMERGENCY 7/23, IF 1.994.**
111. Perl S, Goldman M, Berkovitch M, Kozer E. Characteristics of rotavirus gastroenteritis in hospitalized children in Israel. Isr Med Assoc J. 2011;13(5):274-7. **MEDICINE, GENERAL & INTERNAL 84/153, IF 0.953.**
112. Heyman E, Lahat E, Levin N, Berkovitch M, Gandelman-Marton R. Preliminary efficacy and safety of lacosamide in children with refractory epilepsy. Eur J Paediatr Neurol. **PEDIATRICS 33/109, IF 0.953.**
113. Lahat E, Heyman E, Livne A, Goldman M, Berkovitch M, Zahor D. Iron deficiency in children with attention deficit hyperactivity disorder. Isr Med Assoc J. 2011;13(9):530-3. **MEDICINE, GENERAL & INTERNAL 84/153, IF 0.953.**
-
114. Bar-Oz B, Weber-Schoendorfer C, Berlin M, Clementi M, Di Gianantonio E, de Vries L, De Santis M, Merlob P, Stahl B, Eleftheriou G, Maňáková E, Hubičková – Hlaváčková L, Youngster I, Berkovitch M.
The outcomes of pregnancy in women exposed to the new macrolides in the first trimester: a multicentre, observational study.
Drug Safety. 2012 35(7):589-98
(PHARMACOLOGY & PHARMACY 64/257, IF: 3.435, Q1)
Times Cited: 10
115. Heyman E, Lahat E, Levin N, Berkovitch M, Gandelman-Marton R.
Preliminary efficacy and safety of lacosamide in children with refractory epilepsy. Eur J Paediatr Neurol. 2012 16(1):15-9.
(PEDIATRICS 48/121, IF 2.013, Q2)
Times Cited: 24
116. Cohen H. A, Rozen J, Kristal H, Laks Y, Berkovitch M, Uziel Y, Kozer E, Pomeranz A, Efrat H.
Effect of honey on nocturnal cough and sleep quality: a double-blind, randomized, placebo-controlled study.
Pediatrics. 2012; 130(3):465-471.
(PEDIATRICS 3/121, IF: 5.705, Q1)
Times Cited: 34
117. Kozer E, Lotem Z, Elgarushe M, Torgovicky R, Cohen R, Cohen HA, Berkovitch M.
[RCT of montelukast as prophylaxis for upper respiratory tract infections in](#)

[children.](#)

Pediatrics 2012; 129(2):e285-90.
(PEDIATRICS 3/121, IF: 5.705, Q1)
Times Cited: 6

118. Heyman E, Lavie R, Lahat E, Braunstein R, Bar-Haim A, **Berkovitch M**, Gandelman-Marton
[Lamotrigine serum concentration in children with epilepsy.](#)
Pediatr Neurol. 2012; 47(6):427-30.
(PEDIATRICS 46/121, IF: 2.018, Q2)
Times Cited: 1
119. Massarwi M, Gat-Yablonski G, Shtaiif B, Phillip M, **Berkovitch M**.
[The efficiency of intraosseous human growth hormone administration: a feasibility pilot study model.](#)
Am J Emerg Med. 2013 31(8):1255-9
(EMERGENCY MEDICINE 11/24, IF: 1.494, Q2)
Times Cited: 2
120. Goldstein LH, Berlin M, Saliba W, Elias M, **Berkovitch M**.
[Founding an adverse drug reaction \(ADR\) network: a method for improving doctors spontaneous reporting in a general hospital.](#)
J Clin Pharmacol. 2013 53(11):1220-5
(PHARMACOLOGY & PHARMACY 103/257, IF: 2.812, Q2)
Times Cited: 9
121. Lubart E, **Berkovitch M**, Leibovitz A, Britzi M, Soback S, Bukasov Y, Segal R.
[Pharmacokinetics of ciprofloxacin in hospitalized geriatric patients: comparison between nasogastric tube and oral administration.](#)
Ther Drug Monit. 2013 35(5):653-6.
(MEDICAL LABORATORY TECHNOLOGY 15/30, IF: 2.178, Q2)
Times Cited: 3
122. Youngster I, Zahor DA, Gabis LV, Bar-Chaim A, Benveniste-Levkovitz P, Britzi M, Soback
Baran T, **Berkovitch M**.
CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary study.
Dev Med Child Neurol. 2014; 56(10):990-4.
(PEDIATRICS 16/121, IF: 3.116, Q1)
Times Cited: 14

123. Shihmanter R, Nulman I, Goland S, Caspi A, Bar-Haim A, Harary I, **Berkovitch M**, Arcavi L.
Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure.
J Clin Pharm Ther. 2014; 39(4):432-8.
(PHARMACOLOGY & PHARMACY 188/257, IF: 1.679, Q3)
Times Cited: 6

124. Har-Even R, Stepensky D, Britzi M, Soback S, Chaim AB, Brandriss N, Goldman M, **Berkovitch M**, Kozer E.
Plasma and cerebrospinal fluid concentrations of ibuprofen in pediatric patients and antipyretic effect: Pharmacokinetic-pharmacodynamic modeling analysis.
J Clin Pharmacol. 2014; 54(9):1023-30.
(PHARMACOLOGY & PHARMACY 103/257, IF: 2.812, Q2)
Times Cited: 4

125. Livneh A, Youngster I, El-On Y, **Berkovitch M**, Abu-Kishk I.
The lack of effectiveness of hyperbaric oxygenation as a treatment for Leishmania major in a model.
Acta Parasitol. 2015; 60(2): 345-349.
(PARASITOLOGY 28/36, IF: 1.16, Q4)
Times Cited: 1

126. Abu-Kishk I, Zohar E, **Berkovitch M**, Kozer E, Segulier-Lipszyc E, Baruch K, Elizur A.
Factors associated with empyema in children with community acquired pneumonia.
Minerva Pediatr. 2015; 67(6):473-479
(PEDIATRICS 110/121, IF: 0.764, Q4)
Times Cited: 0

127. Sheinberg R, Heyman E, Dagan Z, Youngster I, Kohn E, Gandelman-Marton R, **Berkovitch M**.
[Correlation between efficacy of levetiracetam and serum levels among children with refractor](#)
Pediatr Neurol. 2015 52(6):624-628.
(PEDIATRICS 46/121, IF: 2.018, Q2)
Times Cited: 4

128. Nir H, **Berkovitch M**, Youngster I, Kozer E, Goldman M, Abu-Kishk I.
[Effect of hyperbaric oxygen therapy on amphotericin-B induced acute renal failure in rats.](#)
Minerva Urol Nefrol. 2015 67(2):97-102.
(UROLOGY & NEPHROLOGY 64/77, IF: 0.984, Q4)

Times Cited: 1

129. Karny-Rahkovich O, Blatt A, Elbaz-Greener GA, Ziv-Baran T, Golik A, **Berkovitch M** .
[Dietary supplement consumption among cardiac patients admitted to internal medicine and cardiac wards.](#)
Cardiol J. 2015; 22(5):510-8.
(CARDIAC & CARDIOVASCULAR SYSTEMS 103/126, IF: 1.256, Q4)
Times Cited: 2
130. Britzi M, **Berkovitch M**, Soback S, Leibovitz A, Segal R, Smagarinsky M, Lubart E. [Roxithromycin Pharmacokinetics in Hospitalized Geriatric Patients: Oral Administration of Whole Versus Crushed Tablets.](#)
Ther Drug Monit. 2015 37(4):512-5.
(MEDICAL LABORATORY TECHNOLOGY 15/30, IF: 2.178, Q2)
Times Cited: 0
131. Rosenfeld-Yehoshua N, Klin B, **Berkovitch M**, Abu-Kishk I.
[Propofol Use in Israeli PICUs.](#)
Pediatr Crit Care Med. 2016 17(3):e117-20.
(PEDIATRICS 9/121, IF: 3.495, Q1)
Times Cited: 2
132. Sabler IM*, **Berkovitch M***, Sandbank J, Kozler E, Dagan Z, Goldman M, Bahat H, Stav K, Ziv-Baran T, Klin B, Abu-Kishk I.
* Equal contribution
[Exposure to Hyperbaric Oxygen Intensified Vancomycin-Induced Nephrotoxicity in Rats.](#) (* Equal contribution)
PLoS One. 2016 11(4):e0152554.
(MULTIDISCIPLINARY SCIENCES 15/64, IF: 2.806, Q1)
Times Cited: 3
133. Klin B, Efrati Y, **Berkovitch M**, Abu-Kishk I.
[Anal fissure in children: a 10-year clinical experience with nifedipine gel and lidocaine.](#)
Minerva Pediatr. 2016 68(3): 196-200.
(PEDIATRICS 110/121, IF: 0.764, Q4)
Times Cited: 1

134. Lazaryan M, Abu-Kishk I, Rosenfeld-Yehoshua N, Berkovitch S, Toledano M, Reshef I, Kan Baran T, **Berkovitch M**.
[Pharmacist Remote Review of Medication Prescriptions for Appropriateness in Pediatric Intensive Care Unit.](#)
 Front Pharmacol. 2016 7:243.
 (PHARMACOLOGY & PHARMACY 33/257, IF: 4.4, Q1)
 Times Cited: 0

135. Iversen OE, Miranda MJ, Ulied A, Soerdal T, Lazarus E, Chokephaibulkit K, Block SL, Skrivanek A, Nur Azurah AG, Fong SM, Dvorak V, Kim KH, Cestero RM, **Berkovitch M**, Ceyhan M, Ellison MC, Ritter MA, Yuan SS, DiNubile MJ, Saah AJ, Luxembourg A.
[Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs 3-Dose Regimen in Women.](#)
 JAMA. 2016 316(22):2411-2421.
 (MEDICINE, GENERAL & INTERNAL 3/155, IF: 44.405, Q1)
 Times Cited: 25

136. Mekory TM, Bahat H, Bar-Oz B, Tal O, **Berkovitch M**, Kozier E.
[The proportion of errors in medical prescriptions and their executions among hospitalized children before and during accreditation.](#)
 Int J Qual Health Care. 2017; 29(3): 366-370.
 (HEALTH POLICY & SERVICES 18/77, IF: 2.342, Q1)
 Times Cited: 0

137. Heyman E, Lahat E, Levin N, Epstein O, Lazinger M, **Berkovitch M**, Gandelman- Marton R.
[Tolerability and efficacy of perampanel in children with refractory epilepsy.](#)
 Dev Med Child Neurol. 2017; 59(4): 441-444.
 (PEDIATRICS 16/121, IF: 3.116, Q1)
 Times Cited: 5

138. Oren-Amit A, **Berkovitch M**, Bahat H, Goldman M, Kozier E, Ziv-Baran T, Abu-Kishk I.
 Complementary and alternative medicine among hospitalized pediatric patients.
 Complement Ther Med. 2017 31:49-52.
 (INTEGRATIVE & COMPLEMENTARY MEDICINE 8/26, IF: 2.013, Q2)
 Times Cited: 0

139. Peled O*, **Berkovitch M***, Rom E, Bilavsky E, Bernfeld Y, Dorfman L, Pappo A,

Ziv-Baran T, Brandriss N, Bar-Haim A, Amir J, Ashkenazi-Hoffnung L.

* Equal contribution

[Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant: A Prospective Pharmacokinetic Study.](#) (*Equal contribution)

Pediatr Infect Dis J. 2017; 36(8): 745-750.

(PEDIATRICS 27/121, IF: 2.486, Q1)

Times Cited: 0

140. Ofek F, Bar Chaim S, Kronenfeld N, Ziv-Baran T, **Berkovitch M**.
International Normalized Ratio Is Significantly Elevated With Rivaroxaban and Apixaban Drug Therapies: A Retrospective Study.
Clin Ther. 2017; 39(5): 1003-1010
(PHARMACOLOGY & PHARMACY 93/257, IF: 2.947, Q2)
Times Cited: 0
141. Theitler J, Brik A, Shaniv D, **Berkovitch M**, Gandelman-Marton R.
Antiepileptic Drug Treatment in Community-Dwelling Older Patients with Epilepsy: A Retrospective Observational Study of Old- Versus New-Generation Antiepileptic Drugs.
Drugs Aging. 2017; 34(6):479-487
(PHARMACOLOGY & PHARMACY 106/257, IF: 2.769, Q2)
Times Cited: 0
142. Svirsky R, Ben-Ami I, **Berkovitch M**, Halperin R, Rozovski U.
[Outcomes of conception subsequent to methotrexate treatment for an unruptured ectopic preg](#)
Int J Gynaecol Obstet. 2017 139(2):170-173.
(OBSTETRICS & GYNECOLOGY 36/80, IF: 2.174, Q2)
Times cited: 0
143. Schwartzberg E, **Berkovitch M**, Nahlieli DD, Nathan J, Gorelik E.
[Pharmacovigilance in Israel - tools, processes, and actions.](#)
Isr J Health Policy Res. 2017; 6(1):29.
(HEALTH POLICIES & SERVICES 47/77, IF: 1.362, Q3)
Times Cited: 0
144. **Berkovitch M**, Shain Y, Kozer E, Goldman M, Abu-Kishk I.
Hyperbaric oxygen treatment and nephrotoxicity induced by gentamicin in rats. BMC Nephro
18(1):347.
(UROLOGY & NEPHROLOGY 31/77, IF: 2.289, Q2)

Times Cited: 0.

145. **Berkovitch M**, Ashkenazi-Hoffnung L, Youngster I, Shaniv D, Dil-Nahlieli D, Gorelik E, Stoller R, Karra N, Schwartzberg E.
Fatal and Near-Fatal Non-allergic Reactions in Patients with Underlying Cardiac disease receiving Benzathine Penicillin G in Israel and Switzerland.
[Front Pharmacol](#). 2017; 8:843.
(PHARMACOLOGY & PHARMACY 33/257, IF: 4.4, Q1)
Times Cited: 0
146. [Rosen L](#), [Guttman N](#), [Myers V](#), [Brown N](#), [Ram A](#), [Hovell M](#), [Breyse P](#), [Rule A](#), [Berkovitch D](#).
Protecting Young Children From Tobacco Smoke Exposure : A Pilot Study of Project Zero E.
Pediatrics 2018; 141(supl 1):s107-s117
(PEDIATRICS 3/121, IF: 5.705, Q1)
Times Cited: 0
147. Kronenfeld N, Ziv-Baran T, Berlin M, Karra N, Dinavitser N, Shaniv D, Cohen R, Schwartzberg **Berkovitch M**.
Chronic Use of Psychotropic Medications in Breastfeeding Women: Is it Safe?
PLoS One. 2018 May 21;13(5):e.
(MULTIDISCIPLINARY SCIENCES 15/64, IF: 2.806, Q1)
Times cited: 6
148. Nir-Neuman H, Abu-Kishk I, Toledano M, Heyman E, Ziv-Baran T, **Berkovitch M**.
[Unlicensed and Off-Label Medication Use in Pediatric and Neonatal Intensive Care Units: No Over a Decade](#).
Adv Ther. 2018 Jun 15.
(PHARMACOLOGY & PHARMACY 91/261, IF:3.085, Q2)
Times cited: 32
149. Barchel D, Stolar O, De-Haan T, Ziv-Baran T, Saban N, Or Fuchs D, Koren G, **Berkovitch M**.
Cannabidiol in Children with Autism Spectrum Disorder- Is It Effective? Parents' Reports.
Front Pharmacol. 2019 Jan 9;9:1521.
(PHARMACOLOGY & PHARMACY 48/261, IF: 3.8, Q1)
150. Berlin M, Barchel D, Gandelman-Martón R, Brandriss N, Blatt I, Ziv-Baran T, Neufeld MY, N, Kohn E, Shaniv D, De-Haan T, Ofek F, Koren G, Stepensky D, **Berkovitch M**.
Therapeutic levetiracetam monitoring during pregnancy: Mind the gap.
Ther Adv Chronic Dis. 2019 May 27;10:2040622319851652.
(PHARMACOLOGY & PHARMACY 36/267, IF: 4.455, Q1)
Times cited: 14

151. Pappo A, Peled O, **Berkovitch M**, Bilavsky E, Rom E, Amir J, Krause I, Yarden Bilavsky H, Scheuerman O, Ashkenazi-Hoffnung L.
[Efficacy and Safety of a Weight-based Dosing Regimen of Valganciclovir for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients.](#) Transplantation. 2019 Aug;103(8):1735.
 (TRANSPLANTATION 5/24, IF: 4.546, Q1)
 Times cited: 12
152. [Kronenfeld N, Gamsu S, Keidar R, Livneh A, Berkovitch M, Goldman M, Bahat H, Shchory-Ziv-Baran T, Abu-Kishk I.](#)
[The Role of an Interventional Program for Improving Pharmacovigilance at a Pediatric Facility](#)
[Front Pharmacol. 2019 Sep10:1004.](#)
 (PHARMACOLOGY & PHARMACY 52/271, IF: 4.225, Q1)
 Times cited: 3
153. [Ofek F, Barchel D, Perets N, Ziv-Baran T, Mahajna A, Filipovich-Rimon T, Garach-Jehoshua M, Berkovitch M.](#)
[International Normalized Ratio as a Screening Test for Assessment of Anticoagulant Activity in Patients Treated With Rivaroxaban or Apixaban: A Pilot Study.](#)
[Front Pharmacol. 2019 Oct 8;10:1177.](#)
 (PHARMACOLOGY & PHARMACY 52/271, IF: 4.225, Q1)
 Times cited: 5
154. [Shchory MP, Goldstein LH, Arcavi L, Shihmanter R, Berkovitch M, Levy A.](#)
[The effect of an intervention program on the knowledge and attitudes among medical staff regarding adverse drug reaction reporting.](#)
[Pharmacoepidemiol Drug Saf. 2020 Oct;29\(10\):1246](#)
 (PHARMACOLOGY & PHARMACY 118/271, IF:2/918, Q2)
 Times cited: 5
155. [Sheinberg R, Siegel EL, Keidar R, Mandel D, Lubetzky R, Kohn E, Livneh A, Tovbin J, Betser M, Moskovich M, Marom R, Ovental A, Daniel S, Factor-Litvak P, Berkovitch M, Levy A.](#)
[Associations between intrauterine exposure to polychlorinated biphenyls on neonatal anogenital distance.](#)
[Reprod Toxicol. 2020 Jun 8;96:67-75.](#)
 (REPRODUCTIVE BIOLOGY 16/30, IF: 3.143, Q3)
 Times cited: 10
156. [Potlog Shchory M, Goldstein LH, Arcavi L, Shihmanter R, Berkovitch M, Levy A.](#) Increasing drug reaction reporting-How can we do better?
[PLoS One. 2020 Aug 13;15\(8\):e0235591.](#)
 (MULTIDISCIPLINARY SCIENCES 26/72, IF: 3.24, Q2)

Times cited: 27

157. Sheinberg R, Siegel EL, Keidar R, Mandel D, Lubetzky R, Kohn E, Livneh A, Tovbin J, Betser M, Moskovich M, Marom R, Ovental A, Daniel S, Factor-Litvak P, **Berkovitch M**, Levy A.

Associations between intrauterine exposure to polychlorinated biphenyls on neonatal ano-genital distance.

Reprod Toxicol. 2020 Sep;96:67-75.

(REPRODUCTIVE BIOLOGY 16/30, IF:3.143, Q2)

Times cited: 10

158. Shklovsky-Kordi A, Gelernter R, **Berkovitch M**, Dagan Z, Kozer E

The Clinical Value of Routine Acetaminophen Level Screening in Pediatric Patients Presenting to Emergency Department.

Isr Med Assoc J. 2020 Sep;22(9):547-551

(MEDICINE GENERAL & INTERNAL 140/167, IF:1.8, Q4)

Times cited: 1

159. Leventer-Roberts M, Grinshpun A, Kohn E, Andra SS, Arora M,

Berkovitch M, Kozer E, Landrigan P, Levine H.

Environmental Tobacco Smoke Exposure among Children by Urinary Biomarkers and Parental Smoking.

Acad Pediatr. 2021 May-Jun;21(4):663-669.

(PEDIATRICS 153/130, IF: 2.993, Q2)

Times cited: 4

160. Gueta I, Braun A, Gilan A, Berlin M, Kohn E, Barchel D, Markovits N,

Berkovitch M, Loebstein R.

Pregnancy outcomes following gestational exposure to papaverine: An observational comparison.

Brit J Clin Pharmacol. 2021 Oct;87(10):3910-3915

(PHARMACOLOGY AND PHARMACY 131/279, IF: 3.716, Q2)

Times cited: 4

161. Klein TT, Kohn E, Klin B, Ziv-Baran T, Kozer E, **Berkovitch M**, Abu Kishk I. sTREM-1 as a diagnostic biomarker for acute appendicitis in children.

Asian J Surg. 2021 Sep; 44(9):1172-1178.

(SURGERY 88/213, IF:2.808, Q2).

162. Rochman M, Mangel L, Mandel D, **Berkovitch M**, Kohn E, Abu Hamad R, Lubetzky R.

Aluminum Content of Human Milk and Antiperspirant Use.

Breastfeed Med. 2021 Aug;16(8):654-659.

(PEDIATRICS 129/130, IF: 2.335, Q3).

Times cited: 3

163. Rosen L, Zucker D, Guttman N, Brown N, Bitan M, Rule A, **Berkovitch M**, Myers V.

Protecting Children from Tobacco Smoke Exposure: A Randomized Controlled Trial of Project

[Exposure.](#)

[Nicotine Tob Res. 2021 Nov 5;23\(12\):2003-2012.](#)

[\(SUBSTANCE ABUSE 4/21, IF:5.825, Q1\)](#)

[Times cited: 3](#)

164. [Dinavitser N, Kohn E, Berlin M, Brandriss N, Bar-Chaim A, Keidar R, Livne A, Stepensky D, **Berkovitch M**, Sheinberg R.](#)

[Levetiracetam in lactation: How much is excreted into human breast milk?.](#)

[Br J Clin Pharmacol. 2022 Jan;88\(1\):199-205.](#)

[\(PHARMACOLOGY AND PHARMACY 131/279, IF: 3.716, Q2\)](#)

[Ties cited: 10](#)

165. [Berlin M, Barchel D, Brik A, Kohn E, Livne A, Keidar R, Tovbin J, Betser M, Moskovich M, Lubetzky R, Ovental A, Factor-Litvak P, Britzi M, Ziv-Baran T, Koren R, Klieger C, **Berkovitch M**, Matok I, Marom R.](#)

[Maternal and Newborn Thyroid Hormone, and the Association with Polychlorinated Biphenyl Burden: The EHF \(Environmental Health Fund\) Birth Cohort.](#)

[Front Pharmacol. 2021 Sep 13](#)

[\(PHARMACOLOGY AND PHARMACY 50/279, IF: 5.988, Q1\)](#)

[Times cited: 8](#)

166. [Shtar G, Rokach L, Shapira B, Kohn E, **Berkovitch M**, Berlin M.](#)

[Explainable multimodal machine learning model for classifying pregnancy drug safety.](#)

[Bioinformatics. 2021 Nov 15;btab769.](#)

[\(BIOCHEMICAL RESEARCH METHODS 8/79, IF:6.931, Q1\)](#)

[Times cited: 10](#)

167. [Treves N, Mor N, Allegaert K, Bassalov H, **Berkovitch M**, Stolar OE, Matok I](#)

[Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis.](#)

[Sci Rep. 2021 Dec 6](#)

[\(MULTIDISCIPLINARY SCIENCES 19/74, IF:4.997, Q2\).](#)

[Times cited: 26](#)

168. [Kohn E, Barchel D, Golik A, Lougassi M, Wainstock T, **Berkovitch M**, Schwartzburd F.](#)

[Analysis of 10 urinary BTEX metabolites using LC-MS/MS.](#)

[Biomed Chromatogr. 2022 Apr;36\(4\):e5302.](#)

[\(CHEMISTRY, ANALYTICAL 70/87, IF 1.911, Q4\)](#)

[Times cited: 2](#)

169. [Kohn E, Dinavitser N, Berlin M, Brandriss N, Bar-Chaim A, Gueta I, Keidar R, Livne A, Stepensky D, **Berkovitch M**, Masarwi M.](#)

[Magnitude of Lamotrigine Exposure through Breastfeeding.](#)

[Breastfeed Med. 2022 Apr;17\(4\):341-348. 19](#)

[\(PEDIATRICS 79/130, IF:2.335, Q3\).](#)

[Times cited: 2](#)

170. [Berman E, Kohn E, **Berkovitch M**, Kovo M, Eyal S.
Lacosamide effects on placental carriers of essential compounds in comparison with valproate
Studies in perfused human placentas.
Epilepsia 2022;63:2949-57
\(CLINICAL NEUROLOGY 27/212, IF: 6.74, Q1\)
Times cited: 5](#)
171. [Guy-Alfandary S, Zhurat S, Berlin M, De Haan T, Gueta I, Shihmanter R,
Golik A, **Berkovitch M**, Eyal S, Goldstein LH.
Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients: A Per
from an Israeli Cross-Sector Collaboration.
Clin Pharmacol Ther. 2022 ; 112\(6\):1156-1158
\(PHARMACOLOGY AND PHARMACY 29/279, IF 7.051, Q1\)
Times cited: 9](#)
172. [Hacohen M, Stolar OM, **Berkovitch M**, Elkana O, Kohn E, Hazan A,

Heyman E, Sobol Y, Waissengreen D, Gal Y, Dinstein I.

Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant
improvements particularly in social symptoms: an open label study.

Transl Psychiatry. 2022 Sep 9;12\(1\):375

\(PSYCHIATRY 29/155, IF 6.8, Q1\)
Times cited: 26](#)
173. [Berlin M, Flor-Hirsch H, Kohn E, Brik A, Keidar R, Livne A, Marom R, Ovental A, Mandel
Lubetzky R, Factor-Litvak P, Tovbin J, Betser M, Moskovich M, Hazan A, Britzi M, Gueta
I, **Berkovitch M**, Matok I,

Hamiel U.

Maternal Exposure to Polychlorinated Biphenyls and Asthma, Allergic Rhinitis and Atopic
Dermatitis in the Offspring: The Environmental Health Fund Birth Cohort.

Front Pharmacol. 2022 Apr 6;13:802974

\(PHARMACOLOGY AND PHARMACY 44/278, IF: 5.6, Q1\)
Times cited: 7](#)
174. [Kohn E, Dinavitser N, Berlin M, Brandriss N, Bar-Chaim A, Gueta I, Keidar R, Livne A, Ste
Berkovitch M, Masarwi M.
Magnitude of Lamotrigine Exposure through Breastfeeding.
Breastfeed Med. 2022 Apr;17\(4\):341-348
PEDIATRICS79/130, IF: 2.335, Q3
Times cited: 0](#)

175. [Stolar O , Hazan A, Enten Vissocker RE, Abu Kishk I, Barchel D, Lezinger M, Dagan A, Nir Treves , Meiri D, **Berkovitch M** , Kohn E, Heyman E.](#)
[Medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: An interim analysis of biochemical safety.](#)
[Front Pharmacol. 2022 Sep 29;13:977484.](#)
[\(PHARMACOLOGY AND PHARMACY 44/278, IF: 5.6, Q1\)](#)
[Times cited: 5](#)
176. [Michael T, Kohn E, Daniel S, Hazan A, **Berkovitch M**, Brik A, Hochwald O, Borenstein-Lev Betser M, Moskovich M, Livne A, Keidar R, Rorman E, Groisman L, Weiner Z, Rabin AM, S A.](#)
[Prenatal exposure to heavy metal mixtures and anthropometric birth outcomes: a cross-section](#)
[Environ Health. 2022 Dec 29;21\(1\):139](#)
[ENVIRONMENTAL SCIENCES 59/275, IF: 6.0, Q1](#)
[Times cited: 16](#)
177. [Ben-Avraham S, Kohn E, Tepper S, Lubetzky R, Mandel D, **Berkovitch M**, Shahr DR.](#)
[Ultra-processed food \(UPF\) intake in pregnancy and maternal and neonatal outcomes.](#)
[Eur J Nutr. 2023 Apr;62\(3\):1403-1413.](#)
[NUTRITION & DIETETICS 29/114, IF: 4.1, Q2](#)
[Times cited: 8](#)
178. [Kohn E, Lezinger M, Daniel S, Masarwi M, Brandriss N, Bar-Chaim A, **Berkovitch M**, Heyman E, Komargodski R.](#)
[Therapeutic drug monitoring of lacosamide among children: is it helpful?](#)
[Front Pharmacol 2023 Jul 6;14:1164902.](#)
[\(PHARMACOLOGY AND PHARMACY 65/354, IF: 4.4, Q1\)](#)
[Times cited: 3](#)
179. [Israel A, Schäffer AA, **Berkovitch M**, Ozeri DJ, Merzon E, Green I, Golan-Cohen A, Rupp](#)
[S, Magen E.](#)
[Glucose-6-Phosphate Dehydrogenase \(G6PD\) Deficiency and Long-Term Risk of Immune-R](#)
[diseases.](#)
[Front Immunol 2023 Mar 24;14: 1232560.](#)
[IMMUNOLOGY 37/181, IF: 5.7, Q1](#)
[Times cited: 5](#)
180. [Hiayev S, Shacham-Shmueli E, **Berkovitch M**, Weiss I, Ashkenazi S, Vexberg MH, Hershko](#)
[Gorelik E, Mayan H, Steinmetz Y, Yanai NB, Schlissel O, Azem M, Gutgold N, Shulman K,](#)
[M, Yarom N, Vishkautzan A, Ganzel C, Gatt ME, Arcavi L, Marom E, Uziely B, Zevin S, M](#)
[Luxenburg O, Ainbinder D. Process of drug registration in Israel: the correlation between the](#)
[discussions within the Ministry of Health and postapproval variations by EMA and/or FDA.](#)
[BMJ Open. 2023 May 4;13\(5\):e067313.](#)
[MEDICINE, GENERAL & INTERNAL 81/329, IF: 2.4, Q1](#)

[Times cited: 1](#)

181. Peled O, Vitzrabin Y, Beit Ner E, Lazaryan M, Berlin M, Barchel D, **Berkovitch M**, Beer Y, [Acceptance rate of clinical pharmacists' recommendations-an ongoing journey for integration](#)
Front Pharmacol. 2023 Sep 13;14:1253990
[\(PHARMACOLOGY AND PHARMACY 65/354, IF: 4.4, Q1\)](#)
[Times cited: 4](#)
182. Israel A, **Berkovitch M**, Merzon E, Golan-Cohen A, Green I, Ruppin E, Vinker S, Magen E. Glucose-6-Phosphate Dehydrogenase Deficiency and Coronavirus Disease 2019
Clin Infect Dis. 2023 Oct 5;77(7):972-975
IMMUNOLOGY 18/181, IF: 8.2, Q1
Times cited: 6
183. Mahajna M, Abu Fanne R, **Berkovitch M**, Tannous E, Vinker S, Green I, Matok I. Effect of Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort Study
Biomedicines. 2023 Dec 7;11(12):3245
[\(PHARMACOLOGY AND PHARMACY 85/354, IF: 3.9, Q1\)](#)
Times cited: 0
184. Taha A, Yeheskeli E, Gavriel H, **Berkovitch M**, Mizrakli Y, Shlamkovitch N, Kohn E. The Safety, Tolerability, and Efficacy of DL-Lactic Acid Syrup (Tonsitin) in Children With Recurrent Tonsillitis: A Pilot Study.
Clin Pediatr (Phila). 2024 Oct;63(10):1395-1405
PEDIATRICS 134/186, IF: 1.0, Q3
Times cited: 0
185. Mahajna M, Abu Fanne R, Odeh M, **Berkovitch M**, Tannous E, Eyal S, Vinker S, Green I, M. Influence of cytochrome P450 2D6*10/*10 genotype on the risk for tramadol associated adverse events: a retrospective cohort study.
Front Pharmacol. 2024 Feb 19
[\(PHARMACOLOGY AND PHARMACY 65/354, IF: 4.4, Q1\)](#)
Times cited: 0
186. Barchel D, Stolar O, Ziv-Baran T, Gueta I, **Berkovitch M**, Kohn E, Bar-Lev Schleider L. Use of Medical Cannabis in Patients with Gilles de la Tourette's Syndrome in a Real-World Study.
Cannabis Cannabinoid Res. 2024 Feb;9(1):293-299.
[\(PHARMACOLOGY & PHARMACY 126/354, IF: 3.1, Q2\)](#)
Times cited: 2
187. Gueta I, Ross J, Sheinberg R, Keidar R, Livne A, **Berkovitch M**, Berlin M, Lubetzky R, Mandel D, Marom R, Ovental A, Hazan A, Betser M, Moskovich M, Efriem S, E. Britzi M. Association between prenatal phthalate exposure and ano-genital indices among offsprings in

cohort.

Heliyon. 2024 Jun 25;10(13):e33633

MULTIDISCIPLINARY SCIENCES 28/134, IF: 3.4, Q1

Times cited: 0

188. David A, Stolar O, **Berkovitch M**, Kohn E, Hazan A, Waissengreen D, Gal E.

Effects of Medical Cannabis Treatment for Autistic Children on Anxiety and Restricted and Repetitive Behaviors and Interests: An Open-Label Study.

Cannabis Cannabinoid Res. 2024 Jul 24

PHARMACOLOGY & PHARMACY 126/354, IF: 3.1, Q1

Times cited: 0

189. Berezovsky E, Kohn E, Britzi M, Efreim S, Berlin M, Oppenheimer S, Avitsur R, Agajany N, **Berkovitch M**, Sheinberg R.

Possible associations between prenatal exposure to environmental pollutants and neurodevelopmental outcome in children.

Reprod Toxicol. 2024 Sep;128:108658

TOXICOLOGY 39/106, IF: 3.3, Q2

Times cited: 2

190. Benassayag Kaduri N, Hazan A, De-Haan T, Kohn E, **Berkovitch M**, Berlin M. Amphetamine/attention deficit hyperactive disorder during breastfeeding and children's neurodevelopmental outcomes: A pilot study.

Psychiatry Res. 2024 Sep;339:116047

PSYCHIATRY 50/279, IF: 4.2, Q1

Times cited: 0

191. Israel A, Raz I, Green I, Golan-Cohen A, **Berkovitch M**, Magen E, Vinker S, Merzon E.

Health disparities in diabetes treatment: The challenge of G6PD deficiency.

Diabetes Res Clin Pract. 2025 Jan;219:111965.

ENDOCRINOLOGY & METABOLISM 21/186, IF: 6.1, Q1

Times cited: 0

192. Siegel EL, Lamb M, Goldsmith J, Rundle A, Neophytou A, **Berkovitch M**, Cohn B, Factor-Litvak F.

Using simulations to explore the conditions under which "true" dose-response relationships are detectable for environmental exposures: polychlorinated biphenyls (PCBs) and birthweight: a pilot study.

Am J Epidemiol. 2025 Feb

Times cited: 0

193. Michael T, Solt I, Daniel S, Levy A, Hochwald O, Borenstein-Levin L, Hazan A, **Berkovitch** A, Rabin AM, Betser M, Moskovich M, Livne A, Keidar R, Schwartzburd F, Weiner Z, Kohn
The association of prenatal volatile organic compounds exposure and newborn anthropometric cross-sectional study.

Int J Hyg Environ Health. 2025 Mar;264:114493.

INFECTIOUS DISEASES 23/132, IF: 4.5, Q1

Times cited: 0

194. Nissimov S, Kohn A, Keidar R, Livne A, Shemer M, Gover A, Hershkovich-Shporen C, **Berkovitch** M, Morag I.

Dexmedetomidine for Less Invasive Surfactant Administration: A Pilot Study.

Paediatr Drugs. 2025 Mar;27(2):247-255

PEDIATRICS 19/186, IF: 3.4, Q1

Times cited: 1

Projects

Year	Investigator (Principal, Other)	Subject	Granted by Institute
2001	PI	A national program for following and reporting adverse drug reactions.	The Israel National Institute for Health Policy Research
2001	PI	Admissions to the pediatric department due to alcohol and drug abuse	The National Institute for Drug Abuse
2002	PI	The efficacy of N-Acetylcystein in acute iron intoxication in rats.	The Chief Scientist- The Ministry of Health
2003	PI	The effect of acute iron intoxication on the glutathione-system enzymes in the liver and erythrocytes	The Hospital for Sick Children, Toronto, Canada and Tel-Aviv University
2004	PI	Admissions to the pediatric emergency department due to alcohol and drug abuse among children	The National Institute for Drug Abuse
2005	PI	Azathioprine (Imuran) use during pregnancy	The Hospital for Sick Children, Toronto, Canada and Tel-Aviv

			University
2005	PI	Scopolamine for organophosphate intoxication	The Chief Scientist - The Ministry of Health
2006	PI	Scopolamine for organophosphate intoxication	The Israeli Defense Force
2006	PI	Admissions to the pediatric emergency department due to alcohol and drug abuse among children	The Chief Scientist - The Ministry of Health
2007	PI	The efficacy of Montelukast in the prevention of recurrent URTI	MSD
2008	PI	The efficacy and safety of ibuprofen suppositories	Reckits Benkizer
2009	PI	The use of Pharmacogenetics in elderly patients treated with Venlafaxine	The Chief Scientist - The Ministry of Health
2009	PI	Investigation of the most effective methods to improve the rate of reporting adverse drug reactions	The Israel National Institute for Health Policy Research
2009	PI	Alcohol and drugs of abuse in the hair and meconium in neonates	The Ministry of Health, Israel – Anti Drug Authorities
2012-2018	Co-Investigator	Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care. Duke Clinical Research Institute. Pediatric Trials Network.	The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), USA.
2012	PI	The effect of phthalates and brominated flame retardants (BFRs) during pregnancy- A Birht Cohort	The Environmental Health Fund
2012	PI	Are breastfed infants exposed to	The Chief Scientist - The

		Brominated Flame Retardants (BFRs) more than formula fed infants?	Ministry of Health
2014	PI	Continuation of treatment from the hospital to the community with a pharmacist	The Israel National Institute for Health Policy Research
2017-2020	PI	Exposure to environmental contaminants-comarison with Haifa Bay	The Ministry of Environment
2017-2019	PI	Exposure to environmental contaminants among fire fighters in Israel	Manof Fund-National Insurance Institute
2017-2018	PI	Environmental contaminants measurement: phthalates and brominated flame retardants in dairy products and infants' formulas	The Chief Scientist - The Ministry of Health
2019-2021	PI	Exposure to air pollution during pregnancy and infancy, adverse respiratory outcomes: comparison between Haifa Bay vs a control group (The Rambam-Assaf Harofeh Birth Cohorts	The Ministry of Environment
2021-2022	Principal investigator	Maternal and newborn exposure to mycotoxins in Israel and the association to baby's development in first months of life	Materna Institute
2021-2022	Principal	The association between prenatal exposure to heavy metals and child neurodevelopment: The Haifa Bay and Central Israel Birth Cohort	Ministry of Health
2023-	Co-	Environmental	MANOF Fund,

2025	investigator	contaminants exposure among fire fighters- Second phase	National Insurance Institute
2024- 2027	Principal investigator	Early recognition of neonatal jaundice application of novel preventive strategies in different health systems	THCS (Transforming Health and Care Systems)- Horizon

Memberships

1988- present	The Israel Society of Clinical Pediatrics.
1988- present	Israel Society of Pediatrics.
1995- present	The Israel Society of Clinical Pharmacology.
1999- present	The European Society for Developmental Perinatal and Paediatric Pharmacology.
1997- present	The European Society of Clinical Pharmacology and Therapeutics.
1992- present	The American Society of Clinical Pharmacology and Therapeutics.
1994- present	The North American Society of Clinical Toxicology.
1997- present	The Israel Society of Toxicology.
1997- present	European Association of Poisons Centres and Clinical Toxicology.
1999- present	European Network of Teratogen Information Service- ENTIS.

Other Relevant Information

C1. ACADEMIC EXPERIENCE

1983-1988	Specialization in Pediatrics, Pediatric Division, Assaf Harofeh Medical Center rotations in the Neonatology Unit, Pediatric Intensive, Care Unit, Pediatric Developmental Unit.
1.4.88-30.6.92	Senior Medical Officer in the Pediatric Day-Care Unit at Assaf Harofeh Medical Center.
1.7.92-30.6.94	Fellowship in Clinical Pharmacology and Toxicology, The Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Canada.
1.7.94-10.10.99	Senior Medical Officer in the Pediatric Day care department, Assaf Harofeh Medical Center.
1995	Lecturer Sackler school of Medicine, Tel-Aviv University.
1999	Specialist in Clinical Pharmacology
1999- 2003	Senior Lecturer in Sackler school of Medicine, Tel-Aviv University.
1999- present	Director – Clinical Pharmacology and Toxicology Unit, Assaf Harofeh Medical Center.
2003- 2007	Chairman- HIPAK- Israel Society of Clinical Pediatrics.
2003- 2006	Chairman- Pediatric Division, Assaf Harofeh Medical Center.
2003- 2011	Associate Clinical Professor in Sackler school of Medicine, Tel-Aviv University.
2011- 2019	Associate Professor in School of Medicine, Tel-Aviv University.
2019-present	Full Professor, School of Medicine, Tel-Aviv University
2022- present	Chair of The Andy-Libach Cathedra of Clinical Pharmacology and Toxicology, School of Medicine, Tel-Aviv University
2005- 2009	Secretary of The Israel Society of Clinical Pharmacology.
2006- 2010	Member of the Committee of ESDP- European Society of Developmental Pharmacology.
2008- 2012	Chairman, The Israel Society of Pediatrics.

2008- 2014	Chairman, Teachers-Students Committee, Sackler School of Medicine, Tel-Aviv University.
2008-2014	Vice Dean for Academic Education at Assaf Harofeh Medical Center, Sackler School of Medicine, Tel-Aviv University.
2008-2018	Member, Teaching Committee Sackler School of Medicine, Tel-Aviv University.
2019 – present	Member, Committee of Academic Nominations, School of Medicine, Tel-Aviv University.
2013-2017	Chairman, Israel Society of Clinical Pharmacology
2014-present	Chairman, National Advisory Committee of Drug Registration, Ministry of Health
2014-present	Chairman, National Advisory Committee on Adverse Drug Reactions, Ministry of Health
2014-present	Member, National Committee on Biosimilar Medications, Ministry of Health
2016-present	Member, National Committee on Genetic Medications, Ministry of Health